Omeros (OMER) News Today

Omeros Corporation (OMER) — Shares moved sharply after a licensing deal and follow‑on analyst and media coverage. The near‑term rally was driven by a large Novo Nordisk agreement, while volatility and a subsequent gap down reflect profit‑taking and heavy intraday volume.

• Positive Sentiment: Novo Nordisk licensed Omeros’ MASP‑3 inhibitor zaltenibart in a deal worth up to $2.1 billion (≈$340M upfront plus milestones). The transaction brings immediate non‑dilutive cash, validates Omeros’ MASP‑3 program, and creates material upside via milestones/royalties if development succeeds. Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn
• Positive Sentiment: HC Wainwright raised near‑ and long‑term EPS forecasts and reiterated a Buy rating with a $20 target, signaling analyst confidence that the company’s pipeline and partner deal materially improve Omeros’ path to profitability. This supports higher valuation expectations over the next several years. FY2025 Earnings Estimate for Omeros Issued By HC Wainwright
• Positive Sentiment: Omeros published peer‑reviewed data showing survival benefits with narsoplimab in TA‑TMA, strengthening the clinical and commercial story for its MASP‑2 program and adding credibility to the company’s complement‑pathway franchise. Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients
• Neutral Sentiment: Wide media and analyst coverage (Seeking Alpha, Zacks, Blockonomi, Motley Fool) amplified investor attention and trading interest after the deal; coverage drove higher volume but is descriptive rather than new fundamental data. Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
• Negative Sentiment: After an initial surge, shares later gapped down amid heavy trading and profit‑taking; MarketBeat flagged the gap‑down and asked whether investors should sell — signaling short‑term volatility risk despite the deal. Traders should expect large intraday swings. Omeros (NASDAQ:OMER) Shares Gap Down - Should You Sell?